This could be supported by the fact that BRCA2 mutation carriers in the surveillance group show more other cancers (i.e., no BC or ovarian cancer) than those in the BRRM group (9% vs. 6%, P = 0.048; Table 1). Here, BRCA2 is linked to breast cancer.